European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization
European Heart Journal: Acute Cardiovascular Care · 2024
DOI: 10.1093/ehjacc/zuae040 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2024. Verfasst von Charlotte J Van Edom und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Diseases, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Fibrinolytic Agents, Heart-Assist Devices. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Fonds Wetenschappelijk Onderzoek Flanders, Abiomed, Amgen.
Abstract (Originalsprache)
Aims
Bleeding and thrombotic complications compromise outcomes in patients undergoing percutaneous mechanical circulatory support (pMCS) with veno-arterial extracorporeal membrane oxygenation (V-A ECMO) and/or microaxial flow pumps like Impella™. Antithrombotic practices are an important determinant of the coagulopathic risk, but standardization in the antithrombotic management during pMCS is lacking. This survey outlines European practices in antithrombotic management in adults on pMCS, making an initial effort to standardize practices, inform future trials, and enhance outcomes. Methods and results This online cross-sectional survey was distributed through digital newsletters and social media platforms by the Association of Acute Cardiovascular Care and the European branch of the Extracorporeal Life Support Organization. The survey was available from 17 April 2023 to 23 May 2023. The target population were European clinicians involved in care for adults on pMCS. We included 105 responses from 26 European countries. Notably, 72.4% of the respondents adhered to locally established anticoagulation protocols, with unfractionated heparin (UFH) being the predominant anticoagulant (Impella™: 97.0% and V-A ECMO: 96.1%). A minority of the respondents, 10.8 and 14.5%, respectively, utilized the anti-factor-Xa assay in parallel with activated partial thromboplastin time for UFH monitoring during Impella™ and V-A ECMO support. Anticoagulant targets varied across institutions. Following acute coronary syndrome without percutaneous coronary intervention (PCI), 54.0 and 42.7% were administered dual antiplatelet therapy during Impella™ and V-A ECMO support, increasing to 93.7 and 84.0% after PCI.
Conclusion
Substantial heterogeneity in antithrombotic practices emerged from participants’ responses, potentially contributing to variable device–associated bleeding and thrombotic complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Diseases, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
- Department of Cardiovascular Sciences, University of Leuven, Herestraat 49, 3000 Leuven, Belgium.
- Department of Respiratory Medicine, Paracelsus Medical University, Prof. Ernst-Nathan Str. 1, 90419 Nürnberg, Germany.
- Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis, Moorselbaan 164, 9300 Aalst, Belgium.
- Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.
- 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, Währinger Gürtel 18-20, 1090 Vienna, Austria.
ORCID-Profile: Charlotte J Van Edom, Justyna Swol, Mario Gramegna, Kurt Huber, Sergio Leonardi, Federico Pappalardo, Susanna Price, Hannah Schaubroeck, Benedikt Schrage, Guido Tavazzi, Pascal Vranckx, Christophe Vandenbriele
Förderung
- Fonds Wetenschappelijk Onderzoek Flanders
- Abiomed
- Amgen
- AstraZeneca
- Bayer
- Boehringer-Ingelheim
- Bristol Myers Squibb
- Chiesi
Zitieren
APA
Van Edom, C. J., Swol, J., Castelein, T., Gramegna, M., Huber, K., Leonardi, S., Mueller, T., Pappalardo, F., Price, S., Schaubroeck, H., Schrage, B., Tavazzi, G., Vercaemst, L., Vranckx, P., & Vandenbriele, C. (2024). European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuae040
Vancouver
Van Edom CJ, Swol J, Castelein T, Gramegna M, Huber K, Leonardi S, et al. European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization. European Heart Journal: Acute Cardiovascular Care. 2024. doi:10.1093/ehjacc/zuae040
BibTeX
@article{VanEdom2024,
author = {Van Edom, Charlotte J and Swol, Justyna and Castelein, Thomas and Gramegna, Mario and Huber, Kurt and Leonardi, Sergio and Mueller, Thomas and Pappalardo, Federico and Price, Susanna and Schaubroeck, Hannah and Schrage, Benedikt and Tavazzi, Guido and Vercaemst, Leen and Vranckx, Pascal and Vandenbriele, Christophe},
title = {European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization},
journal = {European Heart Journal: Acute Cardiovascular Care},
year = {2024},
doi = {10.1093/ehjacc/zuae040}
}
EUVIMED